Bosulif — Competitive Intelligence Brief

Bosulif (bosutinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor. Area: Oncology.

marketed Kinase Inhibitor Tyrosine-protein kinase ABL1 Oncology

Target snapshot

Bosulif (bosutinib) — Pfizer. Bosulif works by blocking the activity of a specific enzyme called tyrosine-protein kinase ABL1, which is involved in the growth and survival of cancer cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bosulif TARGET	bosutinib	Pfizer	marketed	Kinase Inhibitor	Tyrosine-protein kinase ABL1	2012-01-01
Scemblix	ASCIMINIB	Novartis	marketed		Tyrosine-protein kinase ABL1	2021-01-01
Bosulif	Bosutinib Monohydrate	Pfizer	marketed	Kinase Inhibitor	Tyrosine-protein kinase ABL1	2012-01-01
Hernexeos	ZONGERTINIB	Boehringer Ingelheim	marketed	Kinase Inhibitor [EPC]		2025-01-01
Romvimza	VIMSELTINIB	Deciphera Pharms	marketed	Kinase Inhibitor [EPC]		2025-01-01
Wayrilz	RILZABRUTINIB	Genzyme Corp	marketed	Kinase Inhibitor [EPC]		2025-01-01
Itovebi	INAVOLISIB	Genentech Inc	marketed	Kinase Inhibitor [EPC]		2025-01-01

Recent regulatory actions (last 90 days)

• 2026-02-26 — Hernexeos · FDA · approved · US · Boehringer Ingelheim

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Kinase Inhibitor class)

1. Novartis · 5 drugs in this class
2. Pfizer · 3 drugs in this class
3. Bayer · 2 drugs in this class
4. Boehringer Ingelheim · 2 drugs in this class
5. Hoffmann-La Roche · 1 drug in this class
6. Exelixis Inc · 1 drug in this class
7. Novartis Pharm · 1 drug in this class
8. Osi Pharms · 1 drug in this class
9. Exelixis · 1 drug in this class
10. Roche · 1 drug in this class